The Evolving Ms Landscape: Challenges and Opportunities

Chairperson:

Mefkûre Eraksoy¹

Speakers:

Mefkûre Eraksoy,¹ Matthias Mäurer,² Alastair Compston³

1. Department of Neurology, Istanbul Faculty of Medicine and University of Istanbul, Istanbul, Turkey
2. Department of Neurology, Caritas-Hospital Bad Mergentheim, Bad Mergentheim, Germany
3. Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

Disclosure:

Prof Eraksoy has received honoraria, educational grants, and consults from: Biogen, Teva Turkey, Gen Pharma, Bayer Healthcare, Merck Serono, Novartis, and Genzyme. Prof Mäurer has received honoraria, travel grants, and speaker fees from: Biogen Idec, Novartis, Teva, Genzyme, Merck Serono, Boehringer, and Bayer. Prof Compston is a scientific adviser to Lundbeck and has received lecture fees (on behalf of himself and the University of Cambridge); Cambridge University has received endowment for a senior academic position from Genzyme.

Acknowledgements:

Writing assistance provided by Dr Tom Priddle.

Support:

The publication of this article was funded by Genzyme. The views and opinions expressed are those of the authors and not necessarily of Genzyme.

Citation:

EMJ Neurol. 2014;1[1]:36-42. DOI/10.33590/emjneurol/10314635. https://doi.org/10.33590/emjneurol/10314635.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.